|
[Related PubMed/MEDLINE]
Total Number of Papers: 868
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. |
CAPOX, CC, CR, MEC, PTX, TC |
| 2 |
2020 |
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. |
CR, FOS, ISR |
| 3 |
2020 |
A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin. |
--- |
| 4 |
2020 |
A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting. |
HEC, MEC, RA |
| 5 |
2020 |
A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. |
CR, DEX, HEC, NK1RA |
| 6 |
2020 |
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. |
--- |
| 7 |
2020 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. |
--- |
| 8 |
2020 |
Acupuncture therapy for preventing the nausea and vomiting following high emetic risk chemotherapy: A protocol for systematic review and Bayesian Network meta-analysis. |
MRC, NMA, UMCG |
| 9 |
2020 |
Acupuncture treatment for chemotherapy-induced nausea and vomiting: A protocol for systematic review and meta-analysis. |
CBM, CNKI, RevMan |
| 10 |
2020 |
Adherence to ASCO for Prophylaxis of Acute Chemotherapy- Induced Nausea and Vomiting in Iran. |
ASCO |
| 11 |
2020 |
Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy. |
CR |
| 12 |
2020 |
Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. |
ESMO, GITMO, HSCT, MASCC, NK1RA |
| 13 |
2020 |
Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. |
allo-HSCT, FG, MEC or HEC |
| 14 |
2020 |
Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: An updated systematic review and meta-analysis. |
CIs, ORs |
| 15 |
2020 |
Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution. |
--- |
| 16 |
2020 |
Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study. |
CIN, CIV |
| 17 |
2020 |
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. |
HEC, MEC, VAS |
| 18 |
2020 |
Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. |
MBC, ORR, PFS |
| 19 |
2020 |
Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center. |
--- |
| 20 |
2020 |
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. |
HEC, NEPA, NEPA, NK1RA, PSA, QALDs, US |
| 21 |
2020 |
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. |
DEX, HEC, MEC, NEPA, PALO |
| 22 |
2020 |
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. |
DEX, HEC, MEC, NEPA, PALO |
| 23 |
2020 |
Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine. |
QOL |
| 24 |
2020 |
Design of a zero-order sustained release PLGA microspheres for palonosetron hydrochloride with high encapsulation efficiency. |
EE, Pal-MS |
| 25 |
2020 |
Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting - A systematic review and meta-analysis. |
--- |
| 26 |
2020 |
Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India. |
CR, HEC/MEC, NEPA |
| 27 |
2020 |
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. |
5HT3-RAs, ASCT, CT, HD, MD, NK1RAs |
| 28 |
2020 |
Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting. |
AEs, QOL, RCTs, RR, THD |
| 29 |
2020 |
Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research. |
CTCAE, ECOG, HADS, SA, SNAQ, TA |
| 30 |
2020 |
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. |
APR/GRAN, HEC |
| 31 |
2020 |
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. |
CR, HEC, NK-1-RA, OR, PALO-DEX, RNN, SUCRA |
| 32 |
2020 |
Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. |
5-HT3 RA, CC, CR, FLIE, MEC, QOL |
| 33 |
2020 |
Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran. |
--- |
| 34 |
2020 |
Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. |
HSRs |
| 35 |
2020 |
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese". |
AML, CR, TTF |
| 36 |
2020 |
Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective. |
QOL |
| 37 |
2020 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting. |
--- |
| 38 |
2020 |
Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. |
AP, CR, DP, NK-1, OP, RAs |
| 39 |
2020 |
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. |
CY, GTDS |
| 40 |
2020 |
Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA). |
5-HT3RA, AC, NEPA, NK1-RA |
| 41 |
2020 |
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. |
DEX, MCP arm, MEC, TC |
| 42 |
2020 |
Music interventions for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. |
CBM, CENTRAL, CINAHL, CNKI, RCTs |
| 43 |
2020 |
Nanotechnology based blended chitosan-pectin hybrid for safe and efficient consolidative antiemetic and neuro-protective effect of meclizine hydrochloride in chemotherapy induced emesis. |
--- |
| 44 |
2020 |
Nausea and vomiting during post-transplantation cyclophosphamide administration. |
5-HT3 RA, CY/TBI, NK1-RA, PTCy |
| 45 |
2020 |
Nausea in Numbers: Electronic Medical Record Nausea and Vomiting Assessment for Children With Cancer. |
BARF |
| 46 |
2020 |
NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience. |
CR, NSCLC |
| 47 |
2020 |
NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. |
neo |
| 48 |
2020 |
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. |
AC, CR, NEPA |
| 49 |
2020 |
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. |
5-HT3 RA, AEs, CBM, CNKI, RCTs |
| 50 |
2020 |
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. |
CR, HEC |
| 51 |
2020 |
Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. |
CI, OR, RCTs |
| 52 |
2020 |
Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. |
FLIE |
| 53 |
2020 |
Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. |
--- |
| 54 |
2020 |
Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study. |
CR |
| 55 |
2020 |
Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. |
CI, OR |
| 56 |
2020 |
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. |
AC, AE, NK-1, RA |
| 57 |
2020 |
Prevention of chemotherapy-induced nausea and vomiting with acupuncture: A protocol for systematic review and meta-analysis. |
--- |
| 58 |
2020 |
Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. |
HR, NOGGO |
| 59 |
2020 |
Psychometric assessment of the Persian version of short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemetic tool. |
EFA, INVR, MASCC, MAT |
| 60 |
2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. |
CC, CR, QOL |
| 61 |
2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. |
AE, APR, CR, HEC |
| 62 |
2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". |
--- |
| 63 |
2020 |
Revisiting the physiology of nausea and vomiting-challenging the paradigm. |
--- |
| 64 |
2020 |
Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301). |
BMI, CC, CI, CR, MEC, OR |
| 65 |
2020 |
RNA-Seq reveals inflammatory mechanisms of Xiao-Ban-Xia-Tang decoction to ameliorate cisplatin-induced emesis in a rat pica model. |
DEGs, XBXT |
| 66 |
2020 |
Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience. |
--- |
| 67 |
2020 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. |
MEC, RA, TEAEs |
| 68 |
2020 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. |
AC, CR, GI, HEC and MEC |
| 69 |
2020 |
The Antiemetic Effect of Xiao-Ban-Xia-Tang Formula against Cisplatin-Induced Emesis is Mediated through Inhibition of NLRP3 Inflammasome Activation in a Rat Pica Model. |
HE, ROS, XBXT |
| 70 |
2020 |
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. |
CR, HEC |
| 71 |
2020 |
Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis. |
CI, OR, RR |
| 72 |
2020 |
Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. |
--- |
| 73 |
2020 |
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. |
AC, CV, HEC, NK1RA |
| 74 |
2019 |
A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. |
CR, DEX, HEC, NK1RA |
| 75 |
2019 |
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. |
NK-1 |
| 76 |
2019 |
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. |
KSWOG, MEC, QOL |
| 77 |
2019 |
A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. |
auto-SCT, PAL |
| 78 |
2019 |
Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. |
AGA, CGA, HEC, MEC |
| 79 |
2019 |
Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. |
CR |
| 80 |
2019 |
An investigation into the effect of gabapentin capsules on the reduction of nausea and vomiting after chemotherapy in cancerous patients under platinum-based treatment. |
--- |
| 81 |
2019 |
Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. |
--- |
| 82 |
2019 |
Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. |
--- |
| 83 |
2019 |
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. |
--- |
| 84 |
2019 |
Auriculotherapy to control chemotherapy-induced nausea and vomiting in patients with cancer: protocol of a systematic review. |
GRADE, PRISMA-P, RCTs |
| 85 |
2019 |
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. |
HEC, MEC, NEPA, NK-1, RAs |
| 86 |
2019 |
Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. |
HEC |
| 87 |
2019 |
Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study. |
ALL |
| 88 |
2019 |
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. |
AUC, CR, DEX, GRN, NK1RA, OLZ |
| 89 |
2019 |
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. |
CR |
| 90 |
2019 |
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy. |
--- |
| 91 |
2019 |
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. |
HEC, ICER, QALY, SEA |
| 92 |
2019 |
Cost-utility analysis of aprepitant for patients who truly need it in Japan. |
ICER, NK1RA, QALY |
| 93 |
2019 |
Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. |
MEC, RA, TEAEs |
| 94 |
2019 |
Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection: A systematic review and meta-analysis. |
CI, RR |
| 95 |
2019 |
Does the Oral Administration of Ginger Reduce Chemotherapy-Induced Nausea and Vomiting?: A Meta-analysis of 10 Randomized Controlled Trials. |
CI, OR |
| 96 |
2019 |
Effect of acupoint therapies on chemotherapy-induced nausea and vomiting: A systematic review protocol. |
CBM, CNKI, MD, RR, SMD |
| 97 |
2019 |
Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer. |
ES, LC |
| 98 |
2019 |
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. |
CR, DEX, NEPA, OLZ, OR, PAL, PAL0.75 |
| 99 |
2019 |
Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies. |
--- |
| 100 |
2019 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. |
--- |
|
A Search Service for Abbreviation / Long Form
